Immune checkpoint inhibitors (ICI) promote host attack on cancer cells by engaging in the programmed death-ligand 1 (PD-L1)-programmed death 1 (PD-1) pathway and have been shown to have an impressive effect against several types of solid organ cancers, including non-small-cell lung cancer [2,3,4,5]. The gene discussed is CD274; the disease is cancer.